If you have been reading about investigational status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Congebec Logistics is a Quebec City, Quebec based company that provides cold and multi-temperature storage, warehousing and distribution services. It is the second largest refrigerated logistics services provider in Canada. Congebec is considered the 11th largest refrigerated storage company in North America and 18th largest in the world by the International Association of Refrigerated Warehouses (IARW). The company has twelve temperature-controlled facilities across Canada in Boucherville, Sainte-Julie, Montreal, Quebec City, Toronto, Winnipeg, Saskatoon and Calgary with a total of 49,66 million cubic feet (1,406,212) m3) of refrigerated and frozen space. In addition to offering multi-temperature storage and packing services, Congebec also offer logistics and transportation services to its customers.
== Early life == Brian Rafat Awadis was born on November 19, 1996 in San Diego, California, to immigrant Chaldo-Assyrian parents from Tel Keppe, Iraq. His father owns two stores. He graduated from Mira Mesa Senior High School and attended San Diego Miramar College before dropping out during his freshman year to pursue his YouTube career full-time. He can speak the Suret language, although not fluently.
Other populations at increased risk for coeliac disease, include individuals with Down and Turner syndromes, type 1 diabetes, and autoimmune thyroid disease, including both hyperthyroidism (overactive thyroid) and hypothyroidism (underactive thyroid).
On 23 June, Lula separately met with French president Emmanuel Macron and Paris mayor Anne Hidalgo. In October 2023, Brazil said Macron accepted an invitation by Lula to visit the country in the first half of 2024, which was subsequently confirmed by Macron himself during a bilateral meeting with Lula during the COP28 on 2 December 2023. In March 2024, Macron was welcomed by Lula for a three days-long state visit in the northern Brazilian city of Belém, where they met indigenous leader Raoni Metuktire who was awarded the Legion of Honour). Both leaders also announced France and Brazil were launching a four years-long investment plan worth of €1.1 billion to develop the Amazon region including French Guiana. Macron and Lula also visited Itaguaí to launch a third out of four conventional submarines being developed through the French-Brazilian Submarine Development Programme (PROSUB), before visiting Brasília to sign twenty bilateral agreements on 28 March 2024. Macron announced France will help Brazil build its nuclear-powered submarine under PROSUB. During the visit, Lula stated that "Among traditional powers, none is closer to Brazil than France".
==== Metabolism ==== A steady-state plasma level of dofetilide is achieved in 2–3 days. 80% of dofetilide is excreted by the kidneys, so the dose of dofetilide should be adjusted in individuals with chronic kidney disease, based on creatinine clearance. In the kidneys, dofetilide is eliminated via cation exchange (secretion). Agents that interfere with the renal cation exchange system, such as verapamil, cimetidine, hydrochlorothiazide, itraconazole, ketoconazole, prochlorperazine, and trimethoprim should not be administered to individuals taking dofetilide. About 20 percent of dofetilide is metabolized in the liver via the CYP3A4 isoenzyme of the cytochrome P450 enzyme system. Drugs that interfere with the activity of the CYP3A4 isoenzyme can increase serum dofetilide levels. If the renal cation exchange system is interfered with (as with the medications listed above), a larger percentage of dofetilide is cleared via the CYP3A4 isoenzyme system.
Sources: en.wikipedia.org
=== Doug Rattmann === Doug Rattmann, often referred to as the "Ratman" is a character in both Portal and Portal 2. He was a former scientist working at Aperture and one of the few who survived when GLaDOS flooded the facility with neurotoxin. In the two games there are various "Ratman dens", where Doug Rattmann has left scribblings and paintings on walls in hidden rooms. Ratman's full appearance is only seen in the Portal 2: Lab Rat webcomic released by Valve prior to Portal 2's release to tie the story of the two games together. Ratman is the comic's main character. Prior to GLaDOS' rampancy and the neurotoxin release, Doug Rattmann was once an Aperture scientist. Already skeptical of the computer, the man fled from the gas and kept himself hidden from GLaDOS' view, slowly becoming more insane over an unknown stretch of time. Among the wall scribblings in the Portal dens is the sentence "The cake is a lie", which became an internet meme. The Lab Rat comic reveals that, despite his madness, Doug Rattmann identified Chell as a rejected test subject due to her high tenacity, and moved her to the top of the queue for testing. During events in Portal, he worked behind the scenes to scribble messages and warnings to Chell on the walls, leading her out of the testing chambers and towards GLaDOS. After watching her defeat the computer, he managed to escape the facility, but returned to assure Chell would be put in indefinite cryogenic storage animation after she was dragged back inside, suffering a serious injury (a shot in the leg from a turret) to complete this.
Biden earned a Juris Doctor from Syracuse University College of Law in 1968. In his first year of law school, he failed a course because he plagiarized a law review article, but the failing grade was later stricken. His grades were relatively poor, and he graduated 76th in a class of 85. He was admitted to the Delaware bar in 1969. Biden clerked at a law firm headed by prominent local Republican William Prickett in 1968 and self-identified as a Republican. He disliked incumbent Democratic Delaware governor Charles L. Terry's conservative racial politics and supported a more liberal Republican, Russell W. Peterson, who defeated Terry in 1968. Local Republicans attempted to recruit Biden, but he registered as an independent because of his distaste for Republican presidential candidate Richard Nixon.
== Research == A study of 1800 children aged two to twelve in Colac, Australia, tested a program of restricted diet (no carbonated drinks or sweets) and increased exercise. Interim results included a 68% increase in after school activity programs, 21% reduction in television viewing, and an average of 1 kg weight reduction compared to a control group. A survey carried out by the American Obesity Association into parental attitudes towards their children's weight showed the majority of parents think that recess should not be reduced or replaced. Almost 30% said that they were concerned with their child's weight. 35% of parents thought that their child's school was not teaching them enough about childhood obesity, and over 5% thought that childhood obesity was the greatest risk to their child's long-term health. A Northwestern University study indicates that inadequate sleep has a negative impact on a child's performance in school, their emotional and social welfare, and increases their risk of being overweight. This study was the first nationally represented, longitudinal investigation of the correlation between sleep, body mass index (BMI) and overweight status in children between the ages of 3 and 18. The study found that an extra hour of sleep lowered the children's risk of being overweight from 36% to 30%, while it lessened older children's risk from 34% to 30%.
Thiophene is a heterocyclic compound with the formula C4H4S. Consisting of a planar five-membered ring, it is aromatic as indicated by its extensive substitution reactions. It is a colorless liquid with a benzene-like odor. In most of its reactions, it resembles benzene. Compounds analogous to thiophene include furan (C4H4O), selenophene (C4H4Se) and pyrrole (C4H4NH), which each vary by the heteroatom in the ring.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.